Summary
In this paper we present results from a double blind cross over trial with deprenyl, a selective and irreversible monoamine oxidase-B (MAO-B) inhibitor, in 10 patients suffering from amyotrophic lateral sclerosis. The patients were randomised in such a way that half of the patients started with the active drug and half with the placebo treatment. Each patient was given 10 mg deprenyl (eldepryl, 10 mg tablets) per day for 12 weeks and then placebo for the same length of time. There was a drug free period of 12 weeks between the courses. The neurological status of the patients were evaluated every six weeks by using Norris, spinal and bulbar scores and it was observed that all cases deteriorated in their clinical status during the 36 weeks of the controlled study. MAO-B activity in blood platelets was completely inhibited during treatment with deprenyl. In the preliminary analysis performed so far, no obvious retardation in the progress of the disease could be observed with deprenyl treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bonduelle M (1975) Amyotrophic lateral sclerosis. In: Vinken PJ, Bruyn GW (eds) Handbook of neurology, vol 22. Elsevier, Amsterdam, pp 281–338.
Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578.
Criteria for diagnosis of amyotrophic lateral sclerosis (1990) World Neurology 15: 12.
Konradi C, Svoma E, Jellinger K, Riederer P, Denny R, Thibaults J (1988) Topographic immunocytochemical map** of monoamine oxidase-A, monoamine oxidase B and tyrosinhydroxylase in human post mortem brain stem. Neuroscience 26: 791–801.
Plaitakis A, Mandeli J, Yahr MD (1988) Pilot trial of branched chain amino acids in amyotrophic lateral sclerosis. Lancet i: 1015–1018.
Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371.
Riederer P, Youdim M (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with deprenyl. J Neurochem 46: 1359–1365.
Salo PT, Tatton WG (1991) Deprenyl reduces the death of motorneurons caused by axotomy. J Neurosci Res 31: 394–400.
Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag
About this paper
Cite this paper
Jossan, S.S., Ekblom, J., Gudjonsson, O., Hagbarth, KE., Aquilonius, SM. (1994). Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. In: Tipton, K.F., Youdim, M.B.H., Barwell, C.J., Callingham, B.A., Lyles, G.A. (eds) Amine Oxidases: Function and Dysfunction. Journal of Neural Transmission, vol 41. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9324-2_30
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9324-2_30
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82521-1
Online ISBN: 978-3-7091-9324-2
eBook Packages: Springer Book Archive